Peptide Therapeutics Market

Peptide Therapeutics Market: Advancements in the field of Synthetic Peptides and emergence of prominent biopharmaceutical companies are fuelling the growth: Global Industry Analysis and Opportunity Assessment, 2015 - 2025

Introduction

Revival of interest in peptides as potential drug candidates because of their low oral bioavailability has been a major factor fuelling growth of the global peptide therapeutics market. Lack of oral efficacy in peptide drug delivery has actually helped researchers to find innovative methods of peptide drug delivery. However, there is still low acceptance among end users; hence creating awareness could open up opportunities in the market. Peptide therapeutics are used for treating prostrate, breast, ovarian and pancreatic cancers.

Market Value and Forecast

In 2014, the peptide therapeutics market was valued at US$ 16,000.0 Mn and revenue is expected to expand at a CAGR of 10.3% over 2015-2025. This is attributed to advancements in the field of synthetic peptides and emergence of prominent biopharmaceutical companies, fuelled by an increase in prevalence of metabolic disorders.

Market Dynamics

Economic factors such as government policies for start-up companies in emerging economies, increasing FDI in emerging regions and increasing healthcare expenditure are expected to drive market growth globally. Increasing prevalence of cardiovascular & metabolic disorders, advancements in synthetic peptides, emergence of prominent pharmaceutical and biotech companies, high specificity of peptides leading to high clinical value, advanced & strong pipelines and patent expiries among others, are fuelling growth of the global peptide therapeutics market. However, various factors such as increasing commercialisation costs, oral bioavailability of peptide drugs and rapid metabolism and regulatory conditions for peptide drugs is expected to inhibit market growth.

Market Segmentation by Application Type

By application type, the global peptide therapeutics market is segmented into cancer, cardiovascular, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, endocrinology and other applications. The cancer application type segment accounts for highest market share currently, and is expected to remain the leading segment in terms of value during the forecast period.

Market Segmentation by Route Of Administration

In terms of route of administration segmentation, parenteral route of administration is expected to hold more than half the global market share, while revenue from the oral route of administration segment is projected to expand at the highest CAGR over the forecast period as compared to other segments.

Market Segmentation by Drug Type

By drug type segmentation, generic drug type segment is expected to register an exceptional CAGR during the forecast period owing to patent expiries of large number of branded drugs.

Key Regions

On the basis of region, the market in North America currently holds highest share in the global market and the trend is expected to continue over the forecast period. Markets in the Americas and Europe have been estimated to collectively account for over 75% revenue share of the global peptide therapeutics market in 2015. MEA is projected to exhibit above average CAGR in terms of value between 2015 and 2025. The market in MEA is expected to gain a significant BPS over the forecast period, owing to an increase in prevalence of metabolic disorders, coupled with increasing number of pharmaceuticals companies in the region.

Key Players

Key market players covered in this report are AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group and Teva Pharmaceutical Industries Ltd.

Peptide therapeutics are used for treating prostrate, breast, ovarian and pancreatic cancers. Peptides that are antagonists or agonists of specific receptors in oncology are increasingly being tested at the preclinical stages for their efficacy in cancer treatment. Increasing number of oncology studies indicate that there is an enormous cancer patient pool available globally, which is creating a larger niche for cancer application types in the global peptide therapeutics market. As a result, revenue from the cancer application type segment is expected to expand at an above average CAGR of 10.4% and hold the highest market share through 2025.

Revival of interest in peptides as potential drug candidates because of their low oral bioavailability has been a major factor fuelling growth of the global peptide therapeutics market. Lack of oral efficacy in peptide drug delivery has actually helped researchers to find innovative methods of peptide drug delivery. However, there is still low acceptance among end users; hence creating awareness could further open up opportunities in the market.

The peptide therapeutics market is segmented as follows:

  • By application type
  • By route of administration
  • By drug type
  • By region

This report covers the global peptide therapeutics market performance in terms of revenue contribution. The report also includes FMI’s analysis of key trends, drivers, restraints and opportunities that are influencing the global peptide therapeutics market currently. Impact analysis of key growth drivers and restraints is included in this report to better equip clients with crystal-clear decision-making insights.

By application type, the global peptide therapeutics market is segmented into Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders, Endocrinology and Other Applications. The cancer application type of peptide therapeutics accounts for highest market share currently, and is expected to remain the leading segment in terms of value during the forecast period.

In terms of route of administration segmentation, parenteral route of administration segment is expected to hold more than half the global market share, while revenue from the oral route of administration segment is projected to expand at the highest CAGR over the forecast period as compared to other segments.

By drug type segmentation, generic drug type segment is expected to register an exceptionally high CAGR during the forecast period owing to patent expiries of large number of branded drugs.

By region, North America is the largest market in terms of value currently and is expected to retain its position through the forecast period. Markets in the Americas and Europe have been estimated to collectively account for over 75% revenue share of the global peptide therapeutics market in 2015. The market in MEA region is projected to exhibit above average CAGR in terms of value during the forecast period from 2015 to 2025. Market in MEA is expected to gain significant BPS over the forecast period owing to increase in prevalence of metabolic disorders coupled with increasing number of pharmaceuticals companies in the region.

Key market players covered in this report are AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group and Teva Pharmaceutical Industries Ltd. Major players in the peptide therapeutics market are focusing on enhancing their global and regional presence through strategic mergers & acquisitions through expansion of operations.

Key Segments Covered

  • Application Type
    • Cancer
      • Zoladex (Goserelin)
      • Velcade (Bortezomib)
      • Lupron/ Enantone/ Eligard (leuprorelin)
      • Others
    • Cardiovascular
      • Angiomax (Bivalirudin)
      • Integrilin (Eptifibatide)
    • Central Nervous Systems
    • Metabolic Disorders
      • Victoza (Liraglutide)
      • Byetta (Exenatide)
      • Others
    • Infection
      • Incivek (Telaprevir)
      • Victrelis (Boceprevir)
    • Hematological Disorders
      • Firazyr (Icatibant)
      • Kalbitor (Ecallantide)
    • Gastrointestinal Disorders
      • Gattex (Teduglutide)
      • Linzess (Linaclotide)
    • Dermatology
    • Respiratory Disorders
    • Endocrinology
    • Other Applications
  • Route of Administration
    • Parenteral Route
    • Mucosal Route
    • Oral Route
    • Transdermal Route 500+ beds
  • Drug Type
    • Branded
    • Generic

Key Regions/Countries Covered

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Western Europe
    • U.K.
    • France
    • Germany
    • Spain
    • Italy
    • Nordic countries
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
    • China
    • India
    • ASEAN
    • Australia and New Zealand
  • Japan
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Israel
    • Rest of MEA   

Table Of Content

1. Research Methodology

2. Assumptions & Acronyms Used

3. Executive Summary

4. Global Peptide Therapeutics Market – Scenario Forecast

5. Global Peptide Therapeutics Market Dynamics

5.1.1. Drivers 

5.1.2. Restraints

5.1.3. Opportunity

5.2. Global Peptide Therapeutics Market Trends

5.3. Global Peptide Therapeutics Market – Drug Pipelines & Key Regulations

6. Global Peptide Therapeutics Market Analysis and Forecast By Application Type

6.1. Introduction

6.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Application Type

6.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Application Type

6.2. Global Peptide Therapeutics Market Analysis By Application Type 

6.2.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Cancer Application Type 

6.2.1.1. Zoladex (Goserelin)

6.2.1.2. Velcade (Bortezomib)

6.2.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

6.2.1.4. Others

6.2.1.5. Global Peptide Therapeutics Market Absolute $ Opportunity, by Cardiovascular Application Type 

6.2.1.6. Angiomax (Bivalirudin)

6.2.1.8. Integrilin (Eptifibatide)

6.2.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Central Nervous System Application Type

6.2.2.1. Application Type 

6.2.2.2. Copaxone (Glatiramer)

6.2.3. Global Peptide Therapeutics Market Absolute $ Opportunity, by Metabolic Disorders Application Type

6.2.3.1. Victoza (Liraglutide)

6.2.3.2. Byetta (Exenatide)

6.2.3.3. Others

6.2.4. Global Peptide Therapeutics Market Absolute $ Opportunity, by Infection Application Type

6.2.4.1. Incivek (Telaprevir)

6.2.4.2. Victrelis (Boceprevir)

6.2.5. Global Peptide Therapeutics Market Absolute $ Opportunity, by Hematological Disorders Application Type

6.2.5.1. Firazyr (Icatibant)

6.2.5.2. Kalbitor (Ecallantide)

6.2.6. Global Peptide Therapeutics Market Absolute $ Opportunity, by Gastrointestinal Disorders Application Type

6.2.6.1. Gattex (Teduglutide)

6.2.6.2. Linzess (Linaclotide)

6.2.7. Global Peptide Therapeutics Market Absolute $ Opportunity, by Dermatology Application Type

6.2.8. Global Peptide Therapeutics Market Absolute $ Opportunity, by Respiratory Disorders Application Type

6.2.9. Global Peptide Therapeutics Market Absolute $ Opportunity, by Endocrinology Application Type

6.2.10. Global Peptide Therapeutics Market Absolute $ Opportunity, by Other Application Type

6.3. Global Peptide Therapeutics Market Attractiveness Analysis By Application Type

7. Global Peptide Therapeutics Market Analysis and Forecast By Route Of Administration

7.1. Introduction

7.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Route Of Administration

7.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Route Of Administration

7.2. Global Peptide Therapeutics Market Analysis By Route Of Administration 

7.2.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Parenteral Route Of Administration 

7.2.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Mucosal Route Of Administration 

7.2.3. Global Peptide Therapeutics Market Absolute $ Opportunity, by Oral Route Of Administration

7.2.4. Global Peptide Therapeutics Market Absolute $ Opportunity, by Transdermal Route Of Administration

7.3. Global Peptide Therapeutics Market Attractiveness Analysis By Route Of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast By Drug Type

8.1. Introduction

8.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Drug Type

8.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Drug Type

8.2. Global Peptide Therapeutics Market Analysis By Drug Type 

8.2.1.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Branded Drug Type 

8.2.1.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Generic Drug Type 

8.3. Global Peptide Therapeutics Market Attractiveness Analysis By Drug Type

9. Global Peptide Therapeutics Market Analysis and Forecast By Region

9.1. Introduction 

9.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Region

9.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Region

9.1.3. Global Peptide Therapeutics Market Value Share (%) By Region, 2015 & 2025

9.2. Global Peptide Therapeutics Market Attractiveness Analysis By Region

9.3. North America Peptide Therapeutics Market Analysis & Forecast

9.3.1. North America Peptide Therapeutics Market Value Forecast By Country

9.3.1.1. Canada

9.3.1.2. U.S.

9.3.2. North America Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.3.3. North America Peptide Therapeutics Market Value Forecast By Application Type

9.3.3.1. Cancer

9.3.3.1.1. Zoladex (Goserelin)

9.3.3.1.2. Velcade (Bortezomib)

9.3.3.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.3.3.1.4. Others

9.3.3.2. Cardiovascular

9.3.3.2.1. Angiomax (Bivalirudin)

9.3.3.2.2. Integrilin (Eptifibatide)

9.3.3.3. Central Nervous System

9.3.3.3.1. Copaxone (Glatiramer)

9.3.3.4. Metabolic Disorders

9.3.3.4.1. Victoza (Liraglutide)

9.3.3.4.2. Byetta (Exenatide)

9.3.3.4.3. Others

9.3.3.5. Infection

9.3.3.5.1. Incivek (Telaprevir)

9.3.3.5.2. Victrelis (Boceprevir)

9.3.3.6. Hematological Disorders

9.3.3.6.1. Firazyr (Icatibant)

9.3.3.6.2. Kalbitor (Ecallantide)

9.3.3.7. Gastrointestinal Disorders

9.3.3.7.1. Gattex (Teduglutide)

9.3.3.7.2. Linzess (Linaclotide)

9.3.3.8. Dermatology

9.3.3.9. Respiratory Disorders

9.3.3.10. Endocrinology

9.3.3.11. Other Applications 

9.3.4. North America Peptide Therapeutics Market Value Forecast By Route Of Administration

9.3.4.1. Parenteral Route

9.3.4.2. Mucosal Route

9.3.4.3. Oral Route

9.3.4.4. Transdermal Route

9.3.5. North America Peptide Therapeutics Market Value Forecast By Drug Type

9.3.5.1. Branded

9.3.5.2. Generic

9.3.6. North America Peptide Therapeutics Market Impact Analysis

9.4. Latin America Peptide Therapeutics Market Analysis & Forecast

9.4.1. Latin America Peptide Therapeutics Market Trends

9.4.2. Latin America Peptide Therapeutics Market Value Forecast By Country

9.4.2.1. Brazil

9.4.2.2. Mexico

9.4.2.3. Rest Of Latin America

9.4.3. Latin America Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.4.4. Latin America Peptide Therapeutics Market Value Forecast By Application Type

9.4.4.1. Cancer

9.4.4.1.1. Zoladex (Goserelin)

9.4.4.1.2. Velcade (Bortezomib)

9.4.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.4.4.1.4. Others

9.4.4.2. Cardiovascular

9.4.4.2.1. Angiomax (Bivalirudin)

9.4.4.2.2. Integrilin (Eptifibatide)

9.4.4.3. Central Nervous System

9.4.4.3.1. Copaxone (Glatiramer)

9.4.4.4. Metabolic Disorders

9.4.4.4.1. Victoza (Liraglutide)

9.4.4.4.2. Byetta (Exenatide)

9.4.4.4.3. Others

9.4.4.5. Infection

9.4.4.5.1. Incivek (Telaprevir)

9.4.4.5.2. Victrelis (Boceprevir)

9.4.4.6. Hematological Disorders

9.4.4.6.1. Firazyr (Icatibant)

9.4.4.6.2. Kalbitor (Ecallantide)

9.4.4.7. Gastrointestinal Disorders

9.4.4.7.1. Gattex (Teduglutide)

9.4.4.7.2. Linzess (Linaclotide)

9.4.4.8. Dermatology

9.4.4.9. Respiratory Disorders

9.4.4.10. Endocrinology

9.4.4.11. Other Applications 

9.4.5. Latin America Peptide Therapeutics Market Value Forecast By Route Of Administration

9.4.5.1. Parenteral Route

9.4.5.2. Mucosal Route

9.4.5.3. Oral Route

9.4.5.4. Transdermal Route

9.4.6. Latin America Peptide Therapeutics Market Value Forecast By Drug Type

9.4.6.1. Branded

9.4.6.2. Generic

9.4.7. Latin America Peptide Therapeutics Market Impact Analysis

9.5. Western Europe Peptide Therapeutics Market Analysis & Forecast

9.5.1. Western Europe Peptide Therapeutics Market Trends

9.5.2. Western Europe Peptide Therapeutics Market Value Forecast By Country

9.5.2.1. Germany

9.5.2.2. UK

9.5.2.3. France

9.5.2.4. Italy

9.5.2.5. Spain

9.5.2.6. Nordic countries

9.5.2.7. BENELUX

9.5.2.8. Rest Of Western Europe

9.5.3. Western Europe Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.5.4. Western Europe Peptide Therapeutics Market Value Forecast By Application Type

9.5.4.1. Cancer

9.5.4.1.1. Zoladex (Goserelin)

9.5.4.1.2. Velcade (Bortezomib)

9.5.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.5.4.1.4. Others

9.5.4.2. Cardiovascular

9.5.4.2.1. Angiomax (Bivalirudin)

9.5.4.2.2. Integrilin (Eptifibatide)

9.5.4.3. Central Nervous System

9.5.4.3.1. Copaxone (Glatiramer)

9.5.4.4. Metabolic Disorders

9.5.4.4.1. Victoza (Liraglutide)

9.5.4.4.2. Byetta (Exenatide)

9.5.4.4.3. Others

9.5.4.5. Infection

9.5.4.5.1. Incivek (Telaprevir)

9.5.4.5.2. Victrelis (Boceprevir)

9.5.4.6. Hematological Disorders

9.5.4.6.1. Firazyr (Icatibant)

9.5.4.6.2. Kalbitor (Ecallantide)

9.5.4.7. Gastrointestinal Disorders

9.5.4.7.1. Gattex (Teduglutide)

9.5.4.7.2. Linzess (Linaclotide)

9.5.4.8. Dermatology

9.5.4.9. Respiratory Disorders

9.5.4.10. Endocrinology

9.5.4.11. Other Applications 

9.5.5. Western Europe Peptide Therapeutics Market Value Forecast By Route Of Administration

9.5.5.1. Parenteral Route

9.5.5.2. Mucosal Route

9.5.5.3. Oral Route

9.5.5.4. Transdermal Route

9.5.6. Western Europe Peptide Therapeutics Market Value Forecast By Drug Type

9.5.6.1. Branded

9.5.6.2. Generic

9.5.7. Western Europe Peptide Therapeutics Market Impact Analysis

9.6. Eastern Europe Peptide Therapeutics Market Analysis & Forecast

9.6.1. Eastern Europe Peptide Therapeutics Market Trends

9.6.2. Eastern Europe Peptide Therapeutics Market Value Forecast By Country

9.6.2.1. Russia

9.6.2.2. Poland

9.6.2.3. Rest Of Eastern Europe

9.6.3. Eastern Europe Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.6.4. Eastern Europe Peptide Therapeutics Market Value Forecast By Application Type

9.6.4.1. Cancer

9.6.4.1.1. Zoladex (Goserelin)

9.6.4.1.2. Velcade (Bortezomib)

9.6.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.6.4.1.4. Others

9.6.4.2. Cardiovascular

9.6.4.2.1. Angiomax (Bivalirudin)

9.6.4.2.2. Integrilin (Eptifibatide)

9.6.4.3. Central Nervous System

9.6.4.3.1. Copaxone (Glatiramer)

9.6.4.4. Metabolic Disorders

9.6.4.4.1. Victoza (Liraglutide)

9.6.4.4.2. Byetta (Exenatide)

9.6.4.4.3. Others

9.6.4.5. Infection

9.6.4.5.1. Incivek (Telaprevir)

9.6.4.5.2. Victrelis (Boceprevir)

9.6.4.6. Hematological Disorders

9.6.4.6.1. Firazyr (Icatibant)

9.6.4.6.2. Kalbitor (Ecallantide)

9.6.4.7. Gastrointestinal Disorders

9.6.4.7.1. Gattex (Teduglutide)

9.6.4.7.2. Linzess (Linaclotide)

9.6.4.8. Dermatology

9.6.4.9. Respiratory Disorders

9.6.4.10. Endocrinology

9.6.4.11. Other Applications 

9.6.5. Eastern Europe Peptide Therapeutics Market Value Forecast By Route Of Administration

9.6.5.1. Parenteral Route

9.6.5.2. Mucosal Route

9.6.5.3. Oral Route

9.6.5.4. Transdermal Route

9.6.6. Eastern Europe Peptide Therapeutics Market Value Forecast By Drug Type

9.6.6.1. Branded

9.6.6.2. Generic

9.6.7. Eastern Europe Peptide Therapeutics Market Impact Analysis

9.7. APEJ Peptide Therapeutics Market Analysis & Forecast

9.7.1. APEJ Peptide Therapeutics Market Trends

9.7.2. APEJ Peptide Therapeutics Market Value Forecast By Country

9.7.2.1. China

9.7.2.2. India

9.7.2.3. Australia & New Zealand

9.7.2.4. Rest Of APEJ

9.7.3. APEJ Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.7.4. APEJ Peptide Therapeutics Market Value Forecast By Application Type

9.7.4.1. Cancer

9.7.4.1.1. Zoladex (Goserelin)

9.7.4.1.2. Velcade (Bortezomib)

9.7.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.7.4.1.4. Others

9.7.4.2. Cardiovascular

9.7.4.2.1. Angiomax (Bivalirudin)

9.7.4.2.2. Integrilin (Eptifibatide)

9.7.4.3. Central Nervous System

9.7.4.3.1. Copaxone (Glatiramer)

9.7.4.4. Metabolic Disorders

9.7.4.4.1. Victoza (Liraglutide)

9.7.4.4.2. Byetta (Exenatide)

9.7.4.4.3. Others

9.7.4.5. Infection

9.7.4.5.1. Incivek (Telaprevir)

9.7.4.5.2. Victrelis (Boceprevir)

9.7.4.6. Hematological Disorders

9.7.4.6.1. Firazyr (Icatibant)

9.7.4.6.2. Kalbitor (Ecallantide)

9.7.4.7. Gastrointestinal Disorders

9.7.4.7.1. Gattex (Teduglutide)

9.7.4.7.2. Linzess (Linaclotide)

9.7.4.8. Dermatology

9.7.4.9. Respiratory Disorders

9.7.4.10. Endocrinology

9.7.4.11. Other Applications 

9.7.5. APEJ Peptide Therapeutics Market Value Forecast By Route Of Administration

9.7.5.1. Parenteral Route

9.7.5.2. Mucosal Route

9.7.5.3. Oral Route

9.7.5.4. Transdermal Route

9.7.6. APEJ Peptide Therapeutics Market Value Forecast By Drug Type

9.7.6.1. Branded

9.7.6.2. Generic

9.7.7. APEJ Peptide Therapeutics Market Impact Analysis

9.8. Japan Peptide Therapeutics Market Analysis & Forecast

9.8.1. Japan Peptide Therapeutics Market Trends

9.8.2. Japan Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.8.3. Japan Peptide Therapeutics Market Value Forecast By Application Type

9.8.3.1. Cancer

9.8.3.1.1. Zoladex (Goserelin)

9.8.3.1.2. Velcade (Bortezomib)

9.8.3.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.8.3.1.4. Others

9.8.3.2. Cardiovascular

9.8.3.2.1. Angiomax (Bivalirudin)

9.8.3.2.2. Integrilin (Eptifibatide)

9.8.3.3. Central Nervous System

9.8.3.3.1. Copaxone (Glatiramer)

9.8.3.4. Metabolic Disorders

9.8.3.4.1. Victoza (Liraglutide)

9.8.3.4.2. Byetta (Exenatide)

9.8.3.4.3. Others

9.8.3.5. Infection

9.8.3.5.1. Incivek (Telaprevir)

9.8.3.5.2. Victrelis (Boceprevir)

9.8.3.6. Hematological Disorders

9.8.3.6.1. Firazyr (Icatibant)

9.8.3.6.2. Kalbitor (Ecallantide)

9.8.3.7. Gastrointestinal Disorders

9.8.3.7.1. Gattex (Teduglutide)

9.8.3.7.2. Linzess (Linaclotide)

9.8.3.8. Dermatology

9.8.3.9. Respiratory Disorders

9.8.3.10. Endocrinology

9.8.3.11. Other Applications 

9.8.4. Japan Peptide Therapeutics Market Value Forecast By Route Of Administration

9.8.4.1. Parenteral Route

9.8.4.2. Mucosal Route

9.8.4.3. Oral Route

9.8.4.4. Transdermal Route

9.8.5. Japan Peptide Therapeutics Market Value Forecast By Drug Type

9.8.5.1. Branded

9.8.5.2. Generic

9.8.6. Japan Peptide Therapeutics Market Impact Analysis

9.9. MEA Peptide Therapeutics Market Analysis & Forecast

9.9.1. MEA Peptide Therapeutics Market Trends

9.9.2. MEA Peptide Therapeutics Market Value Forecast By Country

9.9.2.1. GCC Countries

9.9.2.2. South Africa

9.9.2.3. Israel

9.9.2.4. Rest Of MEA

9.9.3. MEA Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.9.4. MEA Peptide Therapeutics Market Value Forecast By Application Type

9.9.4.1. Cancer

9.9.4.1.1. Zoladex (Goserelin)

9.9.4.1.2. Velcade (Bortezomib)

9.9.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.9.4.1.4. Others

9.9.4.2. Cardiovascular

9.9.4.2.1. Angiomax (Bivalirudin)

9.9.4.2.2. Integrilin (Eptifibatide)

9.9.4.3. Central Nervous System

9.9.4.3.1. Copaxone (Glatiramer)

9.9.4.4. Metabolic Disorders

9.9.4.4.1. Victoza (Liraglutide)

9.9.4.4.2. Byetta (Exenatide)

9.9.4.4.3. Others

9.9.4.5. Infection

9.9.4.5.1. Incivek (Telaprevir)

9.9.4.5.2. Victrelis (Boceprevir)

9.9.4.6. Hematological Disorders

9.9.4.6.1. Firazyr (Icatibant)

9.9.4.6.2. Kalbitor (Ecallantide)

9.9.4.7. Gastrointestinal Disorders

9.9.4.7.1. Gattex (Teduglutide)

9.9.4.7.2. Linzess (Linaclotide)

9.9.4.8. Dermatology

9.9.4.9. Respiratory Disorders

9.9.4.10. Endocrinology

9.9.4.11. Other Applications 

9.9.5. MEA Peptide Therapeutics Market Value Forecast By Route Of Administration

9.9.5.1. Parenteral Route

9.9.5.2. Mucosal Route

9.9.5.3. Oral Route

9.9.5.4. Transdermal Route

9.9.6. MEA Peptide Therapeutics Market Value Forecast By Drug Type

9.9.6.1. Branded

9.9.6.2. Generic

9.9.7. MEA Peptide Therapeutics Market Impact Analysis

10. Company Profiles

10.1. Company Dashboard

10.2. Company Profiles

10.2.1. AstraZeneca plc

10.2.2. Bachem Holding AG

10.2.3. CordenPharma International 

10.2.4. Eli Lilly and Company

10.2.5. Ipsen S.A

10.2.6. Merck & Co., Inc

10.2.7. Novo Nordisk A/S

10.2.8. PolyPeptide Group

10.2.9. Teva Pharmaceutical Industries Ltd